UK volume price plan for GSK's Tyverb
The UK-based pharmaceutical major GlaxoSmithKline is allegedly considering the offer of a volume pricing model for its oncology drug Tyverb/Tykerb (lapatinib) to the National Health Service in England and Wales. The National Institute for Health and Clinical Excellence (NICE), which advises the NHS outside Scotland on which medicines to prescribe, rejected Tyverb on cost grounds, although a consultation process with the possibility of a positive review has been initiated (Marketletter July 14). GSK refused to comment on the specifics of the claims, which were reported in the Financial Times.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze